Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and NovartisBlockbusters, Bruton's Tyrosine Kinase (BTK) Inhibitors, Business, Clinical Trial Endpoints, Clinical Trials, CNS damage, MS with walking impairment, Multiple Sclerosis, Neurology, Patent Challenges, R&D, Secondary Endpoints, Shares, U.S. Patent Trial and Appeal Board (PTAB)Biogen successfully fended off a patent challenge from generic company Mylan over the multiple sclerosis (MS) drug Tecfidera. Read more February 6, 2020/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/02/Multiple-Sclerosis-Update-BioSpace-2-6-20.jpeg 350 625 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2020-02-06 12:25:202020-02-07 13:54:13Multiple Sclerosis Update: Biogen, Sanofi, Active, Adamas and Novartis